Asthma season is in full swing and AstraZeneca is raising awareness about its severe asthma treatment, Fasenra, as part of its ongoing Stepping Back Out campaign. The latest installment of the ...

Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...

An ad within an ad is the theme of AstraZeneca’s first DTC campaign for Fasenra. In the recently released TV commercial, scientists on TV talk about eosinophilic asthma while potential patients watch ...

No new safety signals were identified in the pediatric trial. The Food and Drug Administration (FDA) has expanded the approval of Fasenra (benralizumab) for add-on maintenance treatment of severe ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated ...

A Phase II investigator-led trial investigating AstraZeneca’s Fasenra (benralizumab) treating eosinophilic exacerbations of ...

MISSISSAUGA, ON, Feb. 26, 2018 /CNW/ - AstraZeneca Canada today announced that Health Canada has approved Fasenra ® (benralizumab injection) as an add-on maintenance treatment for adult patients with ...

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with ...

The FDA has expanded the approval of Fasenra (benralizumab; AstraZeneca) to include self-administration with the Fasenra Pen, a prefilled, single-use autoinjector. The Food and Drug Administration ...

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a rare autoimmune disorder characterized by necrotizing vasculitis of small-to medium-sized blood ...